acivicin has been researched along with Bone Loss, Osteoclastic in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hibi, T; Ikeda, K; Ikeda, Y; Ishizuka, Y; Kawahara, M; Kondo, T; Niida, S; Suzuki, Y; Taniguchi, N | 1 |
1 other study(ies) available for acivicin and Bone Loss, Osteoclastic
Article | Year |
---|---|
Gamma-glutamyltranspeptidase stimulates receptor activator of nuclear factor-kappaB ligand expression independent of its enzymatic activity and serves as a pathological bone-resorbing factor.
Topics: Animals; Bone Marrow Cells; Bone Resorption; Calcitonin; Carrier Proteins; Cell Line, Tumor; Cells, Cultured; Cloning, Molecular; DNA, Complementary; Dose-Response Relationship, Drug; gamma-Glutamyltransferase; Glutathione; Immunoblotting; Isoxazoles; Ligands; Membrane Glycoproteins; Mice; Mice, Inbred C3H; Molecular Sequence Data; Oocytes; Osteoclasts; Protein Binding; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors; Xenopus | 2004 |